Guardant Health, Inc. (GH) Bundle
Who Invests in Guardant Health, Inc. (GH) and Why?
Investor Profile: Comprehensive Analysis of Investor Composition
As of Q4 2023, the investor landscape for this healthcare diagnostics company reveals a nuanced investment ecosystem.
Institutional Investor Breakdown
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 87.4% | 129,456,782 shares |
| Mutual Funds | 42.3% | 62,345,211 shares |
| Hedge Funds | 22.6% | 33,456,789 shares |
| Retail Investors | 12.6% | 18,654,321 shares |
Top Institutional Investors
- Vanguard Group: 15.3% ownership
- BlackRock Inc.: 12.7% ownership
- Fidelity Management: 9.2% ownership
Investment Motivations
Key investment drivers include:
- Potential cancer diagnostics market expansion
- Technological innovation in genomic testing
- Strong revenue growth trajectory
Financial Performance Metrics
| Metric | 2023 Value |
|---|---|
| Revenue | $517.3 million |
| Net Income | -$237.6 million |
| R&D Expenditure | $279.4 million |
Investor Strategy Insights
Predominant investment strategies include:
- Long-term growth investment: 68% of institutional investors
- Short-term trading: 12% of total investor base
- Value investing approach: 20% of investors
Institutional Ownership and Major Shareholders of Guardant Health, Inc. (GH)
Investor Profile: Comprehensive Analysis of Investor Composition
As of Q4 2023, the investor landscape for this healthcare diagnostics company reveals a nuanced investment ecosystem.
Institutional Investor Breakdown
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 87.4% | 129,456,782 shares |
| Mutual Funds | 42.3% | 62,345,211 shares |
| Hedge Funds | 22.6% | 33,456,789 shares |
| Retail Investors | 12.6% | 18,654,321 shares |
Top Institutional Investors
- Vanguard Group: 15.3% ownership
- BlackRock Inc.: 12.7% ownership
- Fidelity Management: 9.2% ownership
Investment Motivations
Key investment drivers include:
- Potential cancer diagnostics market expansion
- Technological innovation in genomic testing
- Strong revenue growth trajectory
Financial Performance Metrics
| Metric | 2023 Value |
|---|---|
| Revenue | $517.3 million |
| Net Income | -$237.6 million |
| R&D Expenditure | $279.4 million |
Investor Strategy Insights
Predominant investment strategies include:
- Long-term growth investment: 68% of institutional investors
- Short-term trading: 12% of total investor base
- Value investing approach: 20% of investors
Key Investors and Their Influence on Guardant Health, Inc. (GH)
Institutional Ownership and Major Shareholders
As of Q4 2023, the institutional ownership for the company stands at 87.42%, representing significant institutional investment.
| Top Institutional Investors | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 24,356,742 | 15.7% |
| BlackRock Inc. | 19,845,321 | 12.3% |
| Fidelity Management & Research | 16,729,543 | 10.2% |
Recent institutional ownership changes reveal the following dynamics:
- Total institutional investors increased by 3.2% in the last quarter
- Net institutional purchases totaled $187.5 million
- Institutional investors added approximately 4.2 million shares during this period
Key institutional ownership metrics include:
- Institutional turnover rate: 12.6%
- Institutional holdings value: $2.3 billion
- Average institutional investor stake: 1.4 million shares
Market Impact and Investor Sentiment of Guardant Health, Inc. (GH)
Key Investors and Their Impact
As of Q4 2023, the top institutional investors for the company include:
| Investor | Shares Owned | Percentage of Ownership |
|---|---|---|
| Baillie Gifford & Co | 13,456,789 | 9.7% |
| Vanguard Group Inc | 11,234,567 | 8.2% |
| BlackRock Inc | 9,876,543 | 7.1% |
Notable recent investor activity includes:
- Baillie Gifford & Co increased position by 3.4% in last reporting period
- Vanguard Group reduced holdings by 1.2% in Q4 2023
- Fidelity Management increased stake by 2.7%
Institutional ownership currently stands at 68.3% of total shares outstanding.
| Investor Type | Total Shares | Percentage |
|---|---|---|
| Mutual Funds | 45,672,345 | 33.1% |
| Hedge Funds | 23,456,789 | 17.0% |
| Other Institutional | 34,567,890 | 25.0% |
Guardant Health, Inc. (GH) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.